TheraRadar
← Back
Data updated: Jun 28, 2026

ITALFARMACO SA

Pharma
OncologyImmunologyGastroenterology Execution: Fair

ITALFARMACO SA is a pharmaceutical company focused on Oncology, Immunology, Gastroenterology. Key products include TIGLUTIK KIT.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

ITALFARMACO SA at a Glance

  • Fast trial execution (21 months median completion)

ITALFARMACO SA's Key Drugs

ITALFARMACO SA's core commercial portfolio centers on TIGLUTIK KIT, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.

TIGLUTIK KIT
CNS
Approved 2018

ITALFARMACO SA's Recent FDA Approvals

New NDA/BLA approvals for ITALFARMACO SA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ITALFARMACO SA's Therapeutic Areas

ITALFARMACO SA's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 70%
0 drugs Phase 2: 3 Phase 1: 1
Immunology 20%
0 drugs Phase 2: 1
Gastroenterology 10%
0 drugs Phase 1: 1

ITALFARMACO SA's Top Competitors

ITALFARMACO SA's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology, Oncology
Pfizer big-pharma
Oncology, Immunology
PF PRISM CV big-pharma
Oncology, Immunology, Gastroenterology

ITALFARMACO SA Pipeline Snapshot

ITALFARMACO SA has 6 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 4 Phase 2 and 2 Phase 1.

0
Phase 3
4
Phase 2
2
Phase 1

Phase 3 Readout Calendar Pro

3 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2026
Givinostat
Polycythemia Vera
Estimated · fresh NCT06093672
Q1 2028
Givinostat
Duchenne Muscular Dystrophy
Estimated · stale NCT05933057
Q4 2029
Givinostat
Duchenne Muscular Dystrophy
Estimated · fresh NCT03373968

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • TIGLUTIK KIT leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • 3 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/3 completed
  • • Speed: 21 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges